Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country

You may also be interested in...



Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy

An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.

Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy

An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.

Diabetes Surge Drives Novo Nordisk To Expand Organically In Emerging Markets As Sanofi Moves To Buy

An expected surge in the number of diabetic patients has prompted the world’s biggest insulin manufacturer to build up resources in emerging markets, most recently unveiling its largest overseas R&D center, while rival Sanofi eyes acquisitions.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC076830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel